Venturis Therapeutics Announces New Leadership Team and Corporate Headquarters Move to Chicago

CHICAGO, IL — August 24, 2026 — Venturis Therapeutics today announced a shareholder led restructuring of the Company, including plans to establish a new corporate office in Chicago, relocating its offices from Dallas. All former Board of Directors and Management of Venturis have resigned. The Company expects to announce the members of its new leadership team and Board of Directors soon. The decision to establish Chicago as the company's primary office reflects the city's position as a major financial center and a hub for pharmaceutical and biotechnology companies. Updated information regarding the Company's leadership, Board of Directors, will be available on the Venturis Therapeutics website as these changes are finalized.

About Venturis Therapeutics

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein-based drug candidates designed to address significant unmet medical needs. The Company's preclinical and clinical development programs include applications in diabetic wounds, severe coronary heart disease, peripheral artery disease, erectile dysfunction, stroke, Parkinson's Disease, and spinal disc disease.

Venturis Therapeutics' lead candidate comes from the family of human fibroblast growth factor , which stimulates the growth of new blood vessels. By promoting neovascularization, this therapeutic has exhibited empirical evidence to increase blood flow to ischemic organs and tissues.

Forward-Looking Statements

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated in these statements. Forward-looking statements include, but are not limited to, statements concerning expectations regarding new research, progress toward or commencement of clinical trials, future business initiatives, and the potential development of the Company's drug candidates.

Factors that could cause actual results to differ materially include, among others, the Company's ability to obtain regulatory approval from the U.S. Food and Drug Administration (FDA) for its drug candidates; market acceptance of any products that may ultimately be developed; developments in the biopharmaceutical industry; future revenues, expenses, margins, and capital requirements; and the Company's overall financial performance.